Dr Reddy’s Duvvada facility receives two observations from USFDA

Pharma company Dr Reddy's Laboratories' Duvvada facility has received two observations from the USFDA for the inspection held between June 13 and June 21.

The observations look more procedural and benign in nature. The first observation is that the acceptance criteria were not established prior to the validation while the second is that the device designs were not correctly translated into product specifications.